골관절염 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Osteoarthritis Drug Market size is expected to reach USD 25.05 Billion in 2034 from USD 11.64 Billion (2025) growing at a CAGR of 8.89% during 2026-2034.

The Global Osteoarthritis Drug Market is expanding due to the rising prevalence of joint disorders among aging populations. Osteoarthritis is one of the most common musculoskeletal conditions worldwide. Increasing obesity rates and sedentary lifestyles contribute to disease incidence. Demand for effective pain management and improved quality of life drives pharmaceutical development.

Current treatments include analgesics, anti-inflammatory drugs, and injectable therapies. Pharmaceutical companies are investing in research for disease-modifying drugs that target underlying cartilage degeneration. Growing healthcare expenditure and improved diagnostic capabilities support market growth. Access to treatment in emerging markets further expands patient reach.

Future prospects depend on successful development of innovative therapies. Advances in biologics and regenerative medicine may transform treatment approaches. Increased awareness and early diagnosis will drive demand for therapeutic solutions. As the global population ages, the osteoarthritis drug market is expected to sustain steady growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Corticosteroids
• NSAIDs and Others
• Viscosupplementation Agents

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Horizon Pharma plc, Pfizer Inc, Sanofi, Anika Therapeutics Inc, Ferring BV, Bioventus Inc, Chugai Pharmaceutical Co Ltd, Alkem Laboratories, Flexion Therapeutics Inc, Zimmer Biomet Holdings Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OSTEOARTHRITIS DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. NSAIDs and Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Viscosupplementation Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OSTEOARTHRITIS DRUG MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OSTEOARTHRITIS DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OSTEOARTHRITIS DRUG MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OSTEOARTHRITIS DRUG INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Horizon Pharma Plc
  • 9.2.2 Pfizer Inc
  • 9.2.3 Sanofi
  • 9.2.4 Anika Therapeutics Inc
  • 9.2.5 Ferring B.V
  • 9.2.6 Bioventus Inc
  • 9.2.7 Chugai Pharmaceutical Co. Ltd
  • 9.2.8 Alkem Laboratories
  • 9.2.9 Flexion Therapeutics Inc
  • 9.2.10 Zimmer Biomet Holdings Inc